AstraZeneca Advances Oral GLP-1 Drug Elecoglipron to Phase 3 Trials

AstraZeneca has announced the progression of its oral GLP-1 drug, elecoglipron, into phase 3 clinical trials, marking a significant step in its pharmaceutical development.